Wistar Scientists Find New Clue To Melanoma Development

November 02, 1998

Philadelphia -- For roughly 20 years, Wistar scientist, Meenhard Herlyn, D.V.M., and his research team have been studying the evolution of melanoma, a potentially deadly skin cancer that is expected to strike 40,300 and kill 17,400 Americans this year.

Dr. Herlyn's most recent studies focus on the "switch" that turns benign lesions into malignancies. "This change," says Dr. Herlyn, "determines the outcome of disease. By identifying the genes that turn the switch on, we can design new therapies to keep it turned off."

Thus far, two genes, the Alphav and Beta3, which are found in the vitronectin receptor (a cell surface glycoprotein that promotes the spread of cells and often is found at sites of skin repair), appear to be involved in melanoma development. "Of the two," says Dr. Herlyn, "we believe the Beta3 subunit is most critical." Supporting documentation for this hypothesis appears in today's American Journal of Pathology.

During their early stage of development, melanoma cells remain in the epidermis, which is the upper layer of the skin, and do not infiltrate the dermis, or lower layer. As soon as these cells begin to express the Beta3 subunit of the vitronectin receptor, however, they become highly aggressive, continuously proliferating and deeply invading, which results in high levels of vascular infiltration and an increased rate of metastasis.

As a result of these findings, Dr. Herlyn's group is developing new inhibitors to block the activity of the vitronectin receptor, one of the most interesting and promising targets for the prevention of angiogenesis.

There are five types of lesions that indicate the level of severity in human melanoma: common acquired nevus, dysplastic nevus, radial growth phase (RGP) primary melanoma, vertical growth phase (VGP) primary melanoma, and metastatic melanoma.

The switch from a benign lesion to a malignancy occurs during the RGP primary melanoma stage, though even then, malignant cells grow only within or in close proximity to the epidermis. It is not until the VGP primary melanoma stage that these same cells gain the ability to invade deeply into the dermis. Consequently, it appears that the most critical step in the progression of melanoma occurs between the RGP and VGP stages, when Beta3 is expressed.
The Wistar Institute, established in 1892, was the first independent medical research facility in the country. For more than 100 years, Wistar scientists have been making history and improving world health through their development of vaccines for diseases that include rabies, German measles, infantile gastroenteritis (rotavirus), and cytomegalovirus; discovery of molecules like interleukin-12, which are helping the immune system fight bacteria, parasites, viruses and cancer; and location of genes that contribute to the development of diseases like breast, lung and prostate cancer. Wistar is a National Cancer Institute Cancer Center.

The Wistar Institute

Related Melanoma Articles from Brightsurf:

Boosting treatments for metastatic melanoma
University of Cincinnati clinician-scientist Soma Sengupta, MD, PhD, says that new findings from her and Daniel Pomeranz Krummel's, PhD, team might have identified a treatment-boosting drug to enhance effectiveness of therapies for metastatic cancer and make them less toxic, giving patients a fighting chance at survival and improved quality of life.

A promising new tool in the fight against melanoma
An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.

New targets for melanoma treatment
A collaborative study led by Monash University's Biomedicine Discovery Institute and the Olivia Newton-John Cancer Research Institute (ONJCRI) has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma.

Innovative smartphone-camera adaptation images melanoma and non-melanoma
An article published in the Journal of Biomedical Optics (JBO), ''Point-of-care, multispectral, smartphone-based dermascopes for dermal lesion screening and erythema monitoring,'' shows that standard smartphone technology can be adapted to image skin lesions, providing a low-cost, accessible medical diagnostic tool for skin cancer.

Antihistamines may help patients with malignant melanoma
Can a very common allergy medicine improve survival among patients suffering from the serious skin cancer, malignant melanoma?

Blood test for deadly eye melanoma
A simple blood test could soon become the latest monitoring tool for the early detection of melanoma in the eye.

Analysis of melanoma in US by age groups
This study used registry data to determine annual rates of melanoma in pediatric, adolescent, young adult and adult age groups, and the findings suggest an apparent decrease among adolescent and young adults between 2006 and 2015 but increases in older adults.

Vitamin D dials down the aggression in melanoma cells
Vitamin D influences the behaviour of melanoma cells in the lab by making them less aggressive, Cancer Research UK scientists have found.

B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer.

Five things to know about melanoma
'Five things to know about ... melanoma' in CMAJ (Canadian Medical Association Journal) provides a brief overview of this malignant skin cancer for physicians and patients.

Read More: Melanoma News and Melanoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.